14,648 Shares in Illumina, Inc. $ILMN Acquired by L2 Asset Management LLC

L2 Asset Management LLC purchased a new stake in Illumina, Inc. (NASDAQ:ILMN) in the second quarter, Holdings Channel.com reports. The institutional investor purchased 14,648 shares of the life sciences company’s stock, valued at approximately $2,576,000.

Several other hedge funds also recently added to or reduced their stakes in ILMN. Elyxium Wealth LLC acquired a new stake in Illumina during the fourth quarter worth approximately $25,000. TD Waterhouse Canada Inc. acquired a new stake in Illumina during the 4th quarter worth $26,000. Laurel Wealth Advisors LLC purchased a new stake in Illumina in the fourth quarter valued at $26,000. Activest Wealth Management boosted its stake in Illumina by 671.9% in the fourth quarter. Activest Wealth Management now owns 247 shares of the life sciences company’s stock valued at $32,000 after acquiring an additional 215 shares in the last quarter. Finally, Keating Financial Advisory Services Inc. purchased a new position in shares of Illumina during the second quarter worth about $32,000. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

ILMN has been the subject of several research reports. Daiwa Securities Group raised Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 target price for the company in a report on Thursday, May 14th. Guggenheim lifted their price target on Illumina from $200.00 to $226.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. Wall Street Zen upgraded Illumina from a “hold” rating to a “buy” rating in a research note on Saturday, August 1st. Piper Sandler restated an “overweight” rating and set a $225.00 target price (up from $200.00) on shares of Illumina in a research report on Monday, August 3rd. Finally, Barclays upped their price target on shares of Illumina from $145.00 to $160.00 and gave the company an “underweight” rating in a research report on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, six have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, Illumina presently has a consensus rating of “Hold” and a consensus target price of $188.40.

Illumina Stock Up 1.7%

Shares of NASDAQ:ILMN opened at $223.22 on Tuesday. The company has a market cap of $33.71 billion, a price-to-earnings ratio of 41.65, a PEG ratio of 3.09 and a beta of 1.44. Illumina, Inc. has a fifty-two week low of $88.00 and a fifty-two week high of $223.97. The firm’s 50-day simple moving average is $189.13 and its 200-day simple moving average is $153.14. The company has a quick ratio of 1.40, a current ratio of 1.80 and a debt-to-equity ratio of 0.53.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, beating analysts’ consensus estimates of $1.23 by $0.08. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The firm had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. During the same quarter last year, the firm earned $1.19 earnings per share. The firm’s revenue was up 9.4% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, equities research analysts predict that Illumina, Inc. will post 5.36 earnings per share for the current year.

Insiders Place Their Bets

In related news, SVP Christensen Jakob Wedel sold 1,033 shares of the company’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $191.52, for a total transaction of $197,840.16. Following the transaction, the senior vice president owned 14,023 shares of the company’s stock, valued at $2,685,684.96. This represents a 6.86% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Patricia Leckman sold 783 shares of the stock in a transaction on Friday, June 5th. The stock was sold at an average price of $162.59, for a total value of $127,307.97. Following the completion of the transaction, the senior vice president owned 21,259 shares of the company’s stock, valued at $3,456,500.81. The trade was a 3.55% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 2,095,958 shares of company stock valued at $401,720,974 in the last three months. 2.90% of the stock is owned by corporate insiders.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.